AR083256A1 - Formas en estado solido del acido (e)-3-[2-(1-{[2-(5-bromo-pirimidin-2-il)-3-ciclopentil-1-metil-1h-indol-6-carbonil]-amino}-ciclobutil)-3-metil-3h-bencimidazol-5-il]-acrilico - Google Patents

Formas en estado solido del acido (e)-3-[2-(1-{[2-(5-bromo-pirimidin-2-il)-3-ciclopentil-1-metil-1h-indol-6-carbonil]-amino}-ciclobutil)-3-metil-3h-bencimidazol-5-il]-acrilico

Info

Publication number
AR083256A1
AR083256A1 ARP110103617A ARP110103617A AR083256A1 AR 083256 A1 AR083256 A1 AR 083256A1 AR P110103617 A ARP110103617 A AR P110103617A AR P110103617 A ARP110103617 A AR P110103617A AR 083256 A1 AR083256 A1 AR 083256A1
Authority
AR
Argentina
Prior art keywords
solid state
ppm
forms
ciclobutil
cyclopentil
Prior art date
Application number
ARP110103617A
Other languages
English (en)
Inventor
Chitra Telang
Zhi Hui Lu
Mayur Suryakant Dudhedia
Richard J Varsolona
Zeren Wang
Danping Li
Rolf Brickl
Shirlynn Stefan-Chen
Jihchin Chung
Siddharthya Mujumdar
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44759789&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR083256(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR083256A1 publication Critical patent/AR083256A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Formas de la sal de sodio del compuesto de fórmula (1), y métodos para su preparación, sus composiciones farmacéuticas, y su uso en el tratamiento de la infección por el Virus de la Hepatitis C (VHC).Reivindicación 2: Una sal cristalina de sodio de acuerdo con la reivindicación 1, caracterizada porque tiene: (a) un modelo de difracción de rayos X en polvo que comprende picos a 7,5 y 20,4 grados 2q (± 0,2 grados 2q) cuando se mide usando radiación CuKa; o (b) un espectro 13C RMN en estado sólido que comprende picos a un desplazamiento químico de 176,8 y 168,4 ppm (± 0,2 ppm); o bien (c) ambos un modelo de difracción de rayos X en polvo que comprende picos a 7,5 y 20,4 grados 2q (± 0,2 grados 2q) cuando se mide usando radiación CuKa y un espectro 13C RMN en estado sólido que comprende picos a un desplazamiento químico de 176,8 ppm y 168,4 ppm (± 0,2 ppm).
ARP110103617A 2010-09-30 2011-09-29 Formas en estado solido del acido (e)-3-[2-(1-{[2-(5-bromo-pirimidin-2-il)-3-ciclopentil-1-metil-1h-indol-6-carbonil]-amino}-ciclobutil)-3-metil-3h-bencimidazol-5-il]-acrilico AR083256A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38824210P 2010-09-30 2010-09-30

Publications (1)

Publication Number Publication Date
AR083256A1 true AR083256A1 (es) 2013-02-13

Family

ID=44759789

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110103617A AR083256A1 (es) 2010-09-30 2011-09-29 Formas en estado solido del acido (e)-3-[2-(1-{[2-(5-bromo-pirimidin-2-il)-3-ciclopentil-1-metil-1h-indol-6-carbonil]-amino}-ciclobutil)-3-metil-3h-bencimidazol-5-il]-acrilico

Country Status (21)

Country Link
US (2) US8598183B2 (es)
EP (1) EP2621921A1 (es)
JP (1) JP2013543495A (es)
KR (1) KR20130108326A (es)
CN (1) CN103153987A (es)
AP (1) AP2013006733A0 (es)
AR (1) AR083256A1 (es)
AU (1) AU2011307346A1 (es)
BR (1) BR112013007700A2 (es)
CA (1) CA2813179A1 (es)
CL (1) CL2013000578A1 (es)
CO (1) CO6700844A2 (es)
EA (1) EA201300422A1 (es)
EC (1) ECSP13012552A (es)
MA (1) MA34548B1 (es)
MX (1) MX2013003551A (es)
PE (1) PE20131351A1 (es)
SG (1) SG188376A1 (es)
TW (1) TW201307327A (es)
UY (1) UY33632A (es)
WO (1) WO2012044520A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8598183B2 (en) * 2010-09-30 2013-12-03 Boehringer Ingelheim International Gmbh Solid state forms of a potent HCV inhibitor
RU2631320C2 (ru) * 2011-12-06 2017-09-21 Санофи Кристаллические формы [(s)-1-карбамоил-2-(фенилпиримидин-2-иламино)этил]амида 2-(2-метиламинопиримидин-4-ил)-1н-индол-5-карбоновой кислоты
US20130261134A1 (en) * 2012-03-30 2013-10-03 Boehringer Ingelheim International Gmbh Mesylate salt forms of a potent hcv inhibitor
WO2014138374A1 (en) 2013-03-08 2014-09-12 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient sub-population

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1033128B2 (en) 1993-09-28 2011-11-23 R.P. Scherer GmbH Soft gelatin capsule manufacture
US5821242A (en) * 1996-06-06 1998-10-13 Eli Lilly And Company Anti-viral compounds
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
DK1718608T3 (da) 2004-02-20 2013-10-14 Boehringer Ingelheim Int Virale polymeraseinhibitorer
CA2597680A1 (en) 2005-02-11 2006-08-17 Boehringer Ingelheim International Gmbh Process for preparing 2,3-disubstituted indoles
KR101374928B1 (ko) 2005-11-09 2014-03-14 노파르티스 아게 일시적 가소제를 사용한 약학 조성물의 제조 방법
US8598183B2 (en) * 2010-09-30 2013-12-03 Boehringer Ingelheim International Gmbh Solid state forms of a potent HCV inhibitor

Also Published As

Publication number Publication date
AU2011307346A1 (en) 2013-02-21
EP2621921A1 (en) 2013-08-07
SG188376A1 (en) 2013-04-30
BR112013007700A2 (pt) 2019-09-24
CO6700844A2 (es) 2013-06-28
JP2013543495A (ja) 2013-12-05
CN103153987A (zh) 2013-06-12
CL2013000578A1 (es) 2013-08-02
UY33632A (es) 2012-04-30
TW201307327A (zh) 2013-02-16
US20120122887A1 (en) 2012-05-17
MX2013003551A (es) 2013-05-01
WO2012044520A1 (en) 2012-04-05
CA2813179A1 (en) 2012-04-05
ECSP13012552A (es) 2013-06-28
PE20131351A1 (es) 2013-12-04
AP2013006733A0 (en) 2013-02-28
MA34548B1 (fr) 2013-09-02
US20140057928A1 (en) 2014-02-27
EA201300422A1 (ru) 2013-09-30
KR20130108326A (ko) 2013-10-02
US8598183B2 (en) 2013-12-03

Similar Documents

Publication Publication Date Title
AR073298A1 (es) Formas cristalinas del 2-tiazolil-4-quinolil-oxi amidas, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento de la infeccion por hcv.
AR114946A2 (es) Formas cristalinas de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
ECSP088859A (es) Nueva forma cristalina vi de la agomelatina, su procedimiento de preparación y las composiciones farmacéuticas que la contienen
CY1118726T1 (el) Αναστολεις αντιγραφης ιων γριπης
AR080494A1 (es) Sales cristalinas de un potente inhibidor del hcv y composiciones farmaceuticas que las contienen
RU2013109393A (ru) Безилатная соль ингибитора втк
WO2014209841A3 (en) Compounds for treating spinal muscular atrophy
BRPI0603043A (pt) forma cristalina iv de agomelatina, um processo para sua preparação e composições farmacêuticas contendo-a
CR8647A (es) Forma cristalina delta-d de clorhidrato de ivabradina, su procedimiento de preparacion y composiciones farmacueticas que la contienen
HRP20170540T1 (hr) Spojevi dimetilbenzojeve kiseline, korisni u liječenju upalnih stanja
HRP20130026T1 (hr) Kristalni oblik posakonazola
AR066158A1 (es) COMPUESTO DE PIRIDAZINA CRISTALINA, UN MÉTODO PARA SU ELABORACIoN Y UNA COMPOSICIoN QUE LO COMPRENDE.
BR112013028679A2 (pt) inibidores do vírus da hepatite c
MY143557A (en) Beta-crystalline form of perindopril arginine salt, process for its preparation, and pharmaceutical compositions containing it
AR073769A1 (es) Inhibidores de la integrasa del vih derivados de azepina y oxazepinas condensadas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de infecciones por vih.
AR083256A1 (es) Formas en estado solido del acido (e)-3-[2-(1-{[2-(5-bromo-pirimidin-2-il)-3-ciclopentil-1-metil-1h-indol-6-carbonil]-amino}-ciclobutil)-3-metil-3h-bencimidazol-5-il]-acrilico
EA200801777A1 (ru) α КРИСТАЛЛИЧЕСКАЯ ФОРМА АРГИНИНОВОЙ СОЛИ ПЕРИНДОПРИЛА, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, КОТОРЫЕ ЕЁ СОДЕРЖАТ
TR201902057T4 (tr) Tetrasiklin bileşikleri.
AR075418A1 (es) Polimorfo cristalino de 3-{[5-(azetidin-1-ilcarbonil)pirazin-2-il]oxi}-5-{[(1s)-1-metil-2-(metiloxi)etil]oxi}-n-(5-metilpirazin-2-il)benzamida,composiciones farmaceuticas que los contienen, proceso para prepararla y uso de las mismas para el tratamiento de la diabetes tipo ii y/u obesidad.
BRPI0606923A2 (pt) substáncia para uso como um medicamento, uso de uma substáncia, método de manufatura de uma substáncia para uso como um medicamento, formulação farmacêutica, e, método de manufatura de uma formulação farmacêutica
IN2012DN06678A (es)
CR20120655A (es) Forma cristalina delta de la sal de arginina de perindoprilo, su procedimiento de preparación, y las composiciones farmacéuticas que la contienen
CY1120728T1 (el) Παραγωγα διαζεπινονης χρησιμα για τη θεραπεια του συνδρομου ευθραυστου χ, της νοσου toy parkinson ή της γαστρο-οισοφαγικης παλινδρομησης
WO2008102037A8 (es) Uso de compuestos como inhibidores de la flavodoxina de helicobacter
TH124708B (th) รูปผลึกของสารยับยั้งออกฤทธิ์ต้าน hcv

Legal Events

Date Code Title Description
FB Suspension of granting procedure